Hepatic and muscle insulin action during late pregnancy in the dog

Cynthia C. Connolly,† Tracy Papa, Marta S. Smith, D. Brooks Lacy, Phillip E. Williams, and Mary Courtney Moore

Departments of 1Molecular Physiology and Biophysics and 2Obstetrics and Gynecology, 
3Diabetes Research and Training Center, and 4Department of Surgery, 
Vanderbilt University School of Medicine, Nashville, Tennessee

Submitted 2 June 2006; accepted in final form 8 September 2006

Connolly CC, Papa T, Smith MS, Lacy DB, Williams PE, Moore MC. Hepatic and muscle insulin action during late pregnancy in the dog. Am J Physiol Regul Integr Comp Physiol 292: R447–R452, 2007. First published September 14, 2006; doi:10.1152/ajpregu.00385.2006.—We evaluated the effects of physiologic increases in insulin on hepatic and peripheral glucose metabolism in nonpregnant (NP) and pregnant (P; 3rd trimester) conscious dogs (n = 9 each) using tracer and arteriovenous difference techniques during a hyperinsulinemic euglycemic clamp. Insulin was initially (−150 to 0 min) infused intraportally at a basal rate. During 0–120 min (Low Insulin), the rate was increased by 0.2 μU·kg⁻¹·min⁻¹, and from 120 to 240 min (High Insulin) insulin was infused at 1.5 μU·kg⁻¹·min⁻¹. Insulin concentrations were significantly higher in NP than P during all periods. Matched subsets (n = 5 NP and 6 P) were identified. In the subsets, insulin was 7 ± 1, 9 ± 1, and 28 ± 3 μU/ml (basal, Low Insulin, and High Insulin, respectively) in NP, and 5 ± 1, 7 ± 1, and 27 ± 3 μU/ml in P. Net hepatic glucose output was suppressed similarly in both subsets (±50% with Low Insulin, 100% with High Insulin), as was endogenous glucose rate of appearance. During High Insulin, NP dogs required more glucose (10.8 ± 1.5 vs. 6.2 ± 1.0 mg·kg⁻¹·min⁻¹, P < 0.05), and hindlimb (primarily skeletal muscle) glucose uptake tended to be greater in NP than P (18.6 ± 2.5 mg/min vs. 13.6 ± 2.0 mg/min, P = 0.06). The normal canine liver remains insulin sensitive during late pregnancy. Differing insulin concentrations in pregnant and nonpregnant women and excessive insulin infusion rates may explain previous findings of hepatic insulin resistance in healthy pregnant women.

† Deceased 21 February 2003.
Address for reprint requests and other correspondence: Mary Courtney Moore, 702 Light Hall, Dept. of Molecular Physiology and Biophysics, Vanderbilt Univ. School of Medicine, Nashville, TN 37232 (e-mail: genie.moore@vanderbilt.edu).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
each experimental period following techniques previously described (12, 30).

Infusions. Each experiment began at −150 min with initiation of a primed (40 μCi), constant infusion (0.35 μCi/min) of [3-3H]glucose (New England Nuclear, Boston, MA) to allow time for tracer equilibration; this infusion continued throughout the experiment. A continuous infusion of Indocyanine Green dye (0.08 mg/min; Sigma, St. Louis, MO) was begun at the same time (3). Also at −150 min, a continuous infusion of somatostatin (0.8 μg·kg−1·min−1; Bachem, Torrance, CA) was begun via peripheral vein. In addition, intraportal infusion of regular pork insulin (Eli Lilly, Indianapolis, IN) was begun at 0.3 μU·kg−1·min−1 via the splenic and jejunal catheters to allow infusion into the hepatic portal circulation. Glucagon (Glucagen; Novo Nordisk, Denmark) was also begun and infused intraarterially at 0.6 ng·kg−1·min−1 for the remainder of the study to maintain basal concentrations. During the basal period, the arterial plasma glucose concentrations were obtained every 5 min, and the insulin infusion rate was adjusted as necessary to maintain euglycemia. No further changes in insulin infusion were made during the period from −60 min through the end of the basal period. At 0 min, the insulin infusion rate was increased by 0.2 μU·kg−1·min−1 over the basal rate (Low Insulin period) (10). At 120 min, the insulin infusion rate was increased in both groups to 1.5 μU·kg−1·min−1 (High Insulin period) (10). During the Low and High Insulin periods, glucose (Dupont; Abbott Laboratories, North Chicago, IL) was infused via peripheral vein as needed to maintain euglycemia.

These studies were begun before it had been established that insulin clearance is altered in pregnancy. Consequently, the same insulin infusion protocol was used in P and NP. However, the insulin concentrations differed significantly between groups in all three periods of study (8 ± 1, 10 ± 1, and 37 ± 4 μU/ml in NP and 4 ± 1, 6 ± 1, and 24 ± 2 μU/ml in P). Since this made interpretation of insulin sensitivity difficult, dogs from each group were selected so that insulin concentrations were matched between groups. Thus, this report includes the data from all 18 dogs but, where appropriate, also includes data from the subsets (6 dogs in the P group and 5 dogs in the NP group, referred to as the “matched subsets”) that had similar insulin concentrations. The conclusions drawn from the data are the same, whether all 18 dogs or only the 11 in the subsets are considered.

Analytical procedures. Analyses have been described in detail previously (12) and included plasma concentrations of glucose, insulin, glucagon, cortisol, estrogen, progesterone, epinephrine, norepinephrine, nonesterified fatty acids, and [3H]glucose content and blood concentrations of lactate, alanine, glycine, theonine, serine, glutamine, glutamate, glycerol, β-hydroxybutyrate, and acetocacetate.

Calculations. Total hepatic blood flow was assessed by hepatic extraction of Indocyanine Green and ultrasonic flow probes (11). Where the ultrasonic probes functioned, balance data were calculated using ultrasonic-derived flows, because this does not require an assumption about the relative proportion of hepatic flow provided by the hepatic artery vs. portal vein. Where both ultrasonic and ICG flows were available, however, calculations performed with the two different sets of flow data do not differ significantly. Net hepatic substrate balance was calculated as LOADout − LOADin. The LOADout = H × Fh and LOADin = (FA × A) + (Fp × P), where A, P, and H are the arterial, portal vein, and hepatic vein substrate concentrations, respectively, and Fh, Fp, and FA are the arterial, portal vein, and total hepatic blood or plasma flow, as appropriate for the particular substrate. Hindlimb balance was calculated as the difference between the iliac vein and arterial blood or plasma substrate concentrations multiplied by the iliac blood or plasma flow (as appropriate). Glucose turnover was calculated with a two-compartment model (23) using dog parameters (13).

Statistical comparisons were made using two-way repeated-measures ANOVA with post hoc analysis employing Tukey’s test. All data in the text are expressed as means ± SE of the three sampling times in each period. Balance data expressed on a weight basis refer to total maternal body weight.

RESULTS

Arterial plasma hormone and glucagon concentrations. The basal insulin infusion rates were 321 ± 48 and 197 ± 53 μU·kg−1·min−1 in the full NP and P groups, respectively (P = 0.1), whereas the rates in the matched subsets were 310 ± 52 and 208 ± 89 μU·kg−1·min−1 in NP and P, respectively (P = 0.3). Arterial plasma insulin was significantly higher in each period in the NP group compared with P when all nine dogs in each group are considered (Fig. 1), as previously mentioned in METHODS, but the concentrations in the matched subsets were very similar, as designed. In the subsets, the concentrations rose from 7 ± 1 (basal) to 9 ± 1 and 28 ± 3 μU/ml in P and from 5 ± 1 to 7 ± 1 and 27 ± 3 μU/ml in P during the Low and High Insulin periods, respectively (Fig. 1).

Arterial plasma glucagon and cortisol concentrations remained basal in both the full groups and the matched subsets throughout the experiments, and they did not differ between groups at any time (Table 1; data shown only for the full groups, which did not differ in these parameters from the matched subsets). Epinephrine and norepinephrine data were also indistinguishable in the two groups, whether the full groups or the matched subsets are considered, with no significant changes over time (data not shown).

Glucose concentrations and blood flow. The plasma glucose concentrations did not change from basal in either group, and they did not differ between groups at any time, whether the full groups or the matched subsets are considered (Fig. 1). Hepatic blood flow was also stable over time in each group and did not differ significantly between groups (Table 1). Hindlimb blood flow increased significantly in NP during High Insulin, and it tended to increase in P (P = 0.1). It was not significantly different between the groups at any time, whether the full groups or the matched subsets were considered.

Glucose kinetics. Net hepatic glucose output (NHGO) in the presence of basal insulinenia was ~70% higher in the P group than in NP (P < 0.05 for comparison of the full groups; P = 0.11 between the matched subsets) (Fig. 2). During Low Insulin, NHGO in the two groups fell ≥50%, and the rates were not different between groups, whether the full groups or the matched subsets are considered (P = 0.3 and 0.4, respectively). Both groups exhibited a low rate of net hepatic glucose uptake during High Insulin. The rate was significantly greater in NP in the matched subsets (0.80 ± 0.17 and 0.11 ± 0.23 mg·kg−1·min−1; P < 0.05) (Fig. 2). Endogenous glucose rate of appearance was suppressed ~50% from basal during Low Insulin, with no differences between groups. During High Insulin, it was suppressed 96 ± 3 and 92 ± 6% in NP and P, respectively (full groups); in the matched subsets, the percent suppression was 92 ± 6 and 88 ± 10% (not different between groups).

The glucose infusion rates required to maintain euglycemia during Low and High Insulin, respectively, were 1.9 ± 0.4 and 10.8 ± 1.5 mg·kg−1·min−1 in NP and 2.0 ± 0.3 and 6.2 ± 1.0 in P (P < 0.05 between groups during High Insulin) (Fig. 1). Hindlimb glucose uptake was no different in the two groups under basal conditions and during Low Insulin (Fig. 2). During High Insulin, hindlimb glucose uptake doubled in NP but
Increased only 50% (in the full P group) or 33% (in the matched subset of P dogs), although there was no statistical difference between groups (Fig. 2).

**Gluconeogenic precursor metabolism.** Gluconeogenic precursor data are presented only for the full groups, as these data did not differ materially from those in the matched subsets. Arterial blood lactate concentrations did not change significantly over time in either group and did not differ between groups. Both groups exhibited net hepatic lactate uptake throughout all study periods, with no difference in rates between groups. Both groups exhibited net hindlimb uptake of lactate during the basal period and switched to net lactate output during Low and High Insulin, with no significant differences between groups and no significant changes over time. (Lactate data not shown.)

Net hepatic alanine uptake did not change significantly over the course of the experiments in either group, but it was significantly lower in P at all times (Table 2). Both groups switched from net hindlimb output to net uptake of alanine during High Insulin (not significantly different, NP vs. P). There were no significant differences in the arterial concentrations and net hepatic or hindlimb balances of the other gluconeogenic amino acids, glutamine, glutamate, glycerol, serine, and threonine (data not shown).

**Table 1. Arterial plasma glucagon and cortisol concentrations and total hepatic and hindlimb blood flow**

<table>
<thead>
<tr>
<th>Group</th>
<th>Experimental Period</th>
<th>Glucagon, ng/l</th>
<th>Cortisol, µg/dl</th>
<th>Hepatic blood flow, ml-kg⁻¹-min⁻¹</th>
<th>Hindlimb blood flow, ml/min</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Basal</td>
<td>Low Insulin</td>
<td>High Insulin</td>
<td>NP</td>
<td>P</td>
</tr>
<tr>
<td></td>
<td></td>
<td>36±2</td>
<td>32±3</td>
<td>25±3</td>
<td>21±2</td>
</tr>
<tr>
<td>NP</td>
<td></td>
<td>36±6</td>
<td>34±6</td>
<td>26±3</td>
<td>21±2</td>
</tr>
<tr>
<td>P</td>
<td></td>
<td>1.8±0.3</td>
<td>2.0±0.2</td>
<td>2.8±0.5</td>
<td>2.6±0.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1.9±0.3</td>
<td>2.0±0.2</td>
<td>2.8±0.5</td>
<td>2.6±0.6</td>
</tr>
</tbody>
</table>

Data are means ± SE for 3 sampling times in each period; n = 9 per group. NP, nonpregnant group; P, pregnant group. There are no differences between groups; *P < 0.05 vs. basal.
Arterial blood glycerol levels fell significantly (~40%) from basal in both groups during hyperinsulinemia and did not differ between groups (Table 2). Net hepatic glycerol uptake declined significantly (28% and 50%, respectively) from basal in both groups during High Insulin and did not differ between groups. Net hindlimb glycerol output declined 1.1 μmol·kg⁻¹·min⁻¹ from basal by the end of study in both groups.

Table 2. Arterial blood alanine and glycerol concentrations (μmol/l), net hepatic uptakes (μmol·kg⁻¹·min⁻¹), and hindlimb balances (μmol/min)

<table>
<thead>
<tr>
<th>Parameter and Group</th>
<th>Basal</th>
<th>Low Insulin</th>
<th>High Insulin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alanine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arterial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NP</td>
<td>324±46</td>
<td>295±38</td>
<td>254±21</td>
</tr>
<tr>
<td>P</td>
<td>226±42</td>
<td>198±32</td>
<td>196±23</td>
</tr>
<tr>
<td>Net hepatic uptake</td>
<td>2.4±0.3</td>
<td>2.8±0.3</td>
<td>2.7±0.3</td>
</tr>
<tr>
<td>NP</td>
<td>1.5±0.3*</td>
<td>1.7±0.2*</td>
<td>1.5±0.3*</td>
</tr>
<tr>
<td>P</td>
<td>1.5±0.3*</td>
<td>1.7±0.2*</td>
<td>1.5±0.3*</td>
</tr>
<tr>
<td>Net hindlimb balance</td>
<td>0.0±1.4</td>
<td>0.2±0.8</td>
<td>-1.3±1.2</td>
</tr>
<tr>
<td>P</td>
<td>-0.2±0.9</td>
<td>0.4±1.4</td>
<td>-2.4±1.4</td>
</tr>
<tr>
<td>Glycerol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arterial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NP</td>
<td>89±16</td>
<td>75±15</td>
<td>55±7†</td>
</tr>
<tr>
<td>P</td>
<td>87±14</td>
<td>63±8†</td>
<td>49±11†</td>
</tr>
<tr>
<td>Net hepatic uptake</td>
<td>1.6±0.3</td>
<td>1.4±0.3</td>
<td>1.2±0.2†</td>
</tr>
<tr>
<td>NP</td>
<td>1.3±0.3</td>
<td>0.9±0.2†</td>
<td>0.7±0.3†</td>
</tr>
<tr>
<td>P</td>
<td>1.3±0.3</td>
<td>0.9±0.2†</td>
<td>0.7±0.3†</td>
</tr>
<tr>
<td>Net hindlimb output</td>
<td>3.0±1.7</td>
<td>2.2±0.8</td>
<td>1.9±0.9</td>
</tr>
<tr>
<td>P</td>
<td>1.1±1.3</td>
<td>0.4±0.7</td>
<td>0.0±0.5†</td>
</tr>
</tbody>
</table>

Values are means ± SE for the 3 time points during each period; n = 9 per group. Negative values for balance data indicate net uptake. *p < 0.05 vs. NP. †p < 0.05 vs. basal.

DISCUSSION

The pregnant dogs in the current report exhibited ~43% reduction in whole body insulin sensitivity, based on the differences in the glucose infusion rate during the High Insulin period. This is very similar to the 45–70% blunting of insulin sensitivity reported in pregnant women during the third trimester (1, 2, 7, 8). The hyperinsulinemic euglycemic clamp technique has been assumed to reflect primarily muscle insulin sensitivity (20). We relied on...
the hindlimb glucose balance to provide an index of muscle insulin sensitivity, since the hindlimb of the dog is 66% skeletal muscle, with most of the remainder of the mass being composed of bone (30). Consistent with the difference between groups in whole body insulin sensitivity, hindlimb glucose uptake during High Insulin was 33% greater in NP than in P, although this did not reach statistical significance.

Basal NHGO and endogenous glucose R₄ were ~70% greater in P vs. NP dogs. An increase in the basal rate of glucose production has previously been observed in normal pregnant women (9), dogs (12), and rats (22). At the lower step of the two-step hyperinsulinemic euglycemic clamp, arterial plasma insulin concentrations increased only 2 μU/ml. This subtle increase in insulin was sufficient to decrease NHGO by 50% or more in both the pregnant and the nonpregnant dogs, as previously demonstrated in normal dogs of both sexes (10). Cumulatively, the decreases in NHGO during the three periods were very similar between the two groups, with the change from basal totaling 1.9 ± 0.3 and 2.2 ± 0.4 mg·kg⁻¹·min⁻¹ in the matched subsets of NP and P, respectively (Δ1.7 ± 0.1 and 2.3 ± 0.4 mg·kg⁻¹·min⁻¹ in the full groups). Similarly, the percentage suppression of glucose rate of appearance was not different between groups at either step. These data are consistent with unimpaired hepatic insulin action in the pregnant animals and in general agreement with the findings of Catalano et al. (9) in normal-weight women in late pregnancy.

Two reports in vivo have suggested that loss of hepatic insulin sensitivity occurs in obese glucose-tolerant women (5, 29). A longitudinal study, utilizing euglycemic clamps with two rates of insulin infusion (resulting in insulin concentrations of ~50 and 100 μU/ml, respectively) was carried out in eight obese women with normal glucose tolerance (5). In that study, there was ~90% suppression of EGP during the 50 μU/ml clamp in the pregravid state and late pregnancy (34–36 wk). In contrast, suppression of EGP during the 100 μU/ml study was modestly but significantly impaired in late pregnancy (93% suppression, compared with 97% in the pregravid state). The investigators concluded that the combination of obesity and pregnancy created sufficient stress to make evident a loss of hepatic insulin sensitivity in the third trimester (5). However, insulin concentrations during the clamps differed (94 and 71 μU/ml in the pregravid and late pregnancy studies, respectively) (5), presumably because of increased insulin clearance in late pregnancy (4). This strongly suggests that if the insulin concentrations in the third trimester study had been equivalent to those in the pregravid study, suppression of EGP in the third trimester would have been as complete as in the study prior to pregnancy. The second investigation in which hepatic insulin resistance was observed in late human pregnancy also involved repeated euglycemic hyperinsulinemic clamps in a small group (n = 6) of obese women, but utilized a single insulin infusion rate. Again, insulin concentrations tended to be lower during the third trimester than in the nonpregnant study in the same subjects (88 vs. 101 μU/ml), although this did not reach statistical significance (29). EGP was suppressed 77–79% within 2 h during the second trimester and 15.6 wk postpartum, but it was only suppressed 39% during the third trimester (29). However, after 4 h of insulin infusion, EGP in all of the studies was suppressed ~86% (29). Hepatic insulin resistance has been reported in both rabbits and rats during the third trimester of pregnancy (19, 25). However, the insulin concentrations achieved were supraphysiologic (10- to 50-fold basal), not optimal for examining hepatic insulin sensitivity.

The molecular basis for the insulin resistance of pregnancy is still poorly understood (32). Most investigations have found insulin receptor binding to be unimpaired in normal pregnancies and in those complicated by gestational diabetes, consistent with a postreceptor defect (26, 32). Yamada et al. (31) reported that GLUT4 protein content was reduced in adipose tissue but not skeletal muscle during pregnancy in normal and streptozotocin-diabetic rats, a finding in general agreement with data from a small number of pregnant women (15). A number of defects suggesting impaired insulin signaling have been noted in pregnancy. These include impaired insulin receptor tyrosine kinase activity (14, 27), decreased insulin receptor substrate-1 (IRS-1) expression and/or altered phosphorylation of IRS-1 (6, 26), redistribution of phosphatidylinositol 3-kinase (PI3-kinase) and/or increased expression of the p85α-subunit of PI3-kinase (21, 28). In the late-pregnant rat, assessment of insulin receptor expression and tyrosine phosphorylation in liver, skeletal muscle, and adipose tissue indicated that muscle and adipose tissue were the tissues with the most significant reduction in insulin action, with liver being less affected (18). Subsequent studies also indicated that the phosphorylation and expression of IRS-1 was less impaired in the liver than in skeletal muscle and adipose tissue during late pregnancy (17). In contrast, Saad et al. (26) found that IRS-1 protein and the association of IRS-1 with PI3-kinase were significantly and similarly reduced in both skeletal muscle and liver in the pregnant rat. An increase in skeletal muscle IRS-1 protein and a decrease of the p85α-subunit of PI3-kinase were observed in nonobese, nondiabetic women postpartum, compared with an assessment carried out in the same women during late pregnancy (21). No assessment of liver protein expression could be made, however.
There was no evidence of a loss of insulin’s ability to suppress proteolysis or lipolysis in the nonhepatic tissues. The hindlimb balances of alanine and the other gluconeogenic amino acids were not different between pregnant and nonpregnant dogs at any time. Glycerol concentrations were similarly suppressed by insulin in the NP and P groups, and net hindlimb glycerol output declined 1.1 μmol·kg⁻¹·min⁻¹ from basal in both groups during High Insulin. Since glycerol is a sensitive index of lipolysis, it appears that the insulin resistance observed was limited to glucose metabolism.

The current studies are unique in being among the first to examine hepatic insulin sensitivity in pregnancy in a model in which a physiologic elevation of insulin could be brought about, with the insulin concentrations closely matched in the pregnant and nonpregnant states. There was no evidence of impaired hepatic insulin sensitivity under these conditions. In agreement with in vitro findings (26) and a previous investigation in lean women (9), it appears that insulin action in the liver is preserved in the third trimester of normal pregnancy. In previous studies where loss of hepatic insulin sensitivity has been observed in the last trimester of human pregnancy, the findings are likely explained by lower insulin concentrations during studies conducted in the third trimester and/or the use of insulin infusion rates too high to isolate the liver’s response.

REFERENCES

This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases Grant R01-DK-58134 and Diabetes Research and Training Center Grant AM20593.